The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | J | Antiinfectives for systemic use | |
| 2 | J07 | Vaccines | |
| 3 | J07B | Viral vaccines | |
| 4 | J07BK | Varicella zoster vaccines |
| Code | Title | |
|---|---|---|
| J07BK01 | Varicella, live attenuated | |
| J07BK02 | Zoster, live attenuated | |
| J07BK03 |
| Active Ingredient | Description | |
|---|---|---|
| Varicella, live attenuated |
Natural infection induces a cellular and humoral immune response to the varicella-zoster virus, which can be rapidly detected following infection. IgG, IgM and IgA directed against viral proteins usually appear at the same time that a cellular immune response can be demonstrated, making the relative contribution of humoral and cellular immunity to disease progression difficult to ascertain. Vaccination has been shown to induce both humoral and cell-mediated types of immunity. |
|
| Attenuated varicella-zoster virus |
Varicella-zoster virus vaccine was shown to boost VZV-specific immunity, which is thought to be the mechanism by which it protects against zoster and its complications. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| SHINGRIX Powder for suspension for injection | European Medicines Agency (EU) | MPI, EU: SmPC | |
| VARILRIX Powder and solvent for solution for injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| ZOSTAVAX Powder and solvent for suspension for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
